Introduction
============

MALDI-MS was developed in the late 1980s and since then it has become a powerful tool for the analysis of large biomolecules, such as proteins, peptides, and nucleic acids, etc. \[[@B1]\]. Two important factors that involved in the ionization of analytes in the MALDI processing are laser and matrices. MALDI techniques commonly employ the use of UV lasers such as nitrogen lasers (337 nm) and frequency-tripled and quadrupled Nd: YAG lasers (355 nm and 266 nm, respectively) as a energy source. Moreover, radiation from IR laser such as Er: YAG lasers and CO~2~ are also employed \[[@B2]\]. Several modifications have been made on UV lasers to improve the performance. Recently, a modified laser named "smartbeam" has been introduced by the Bruker which is a combination of the speed of a solid-state-laser and the wide range of nitrogen lasers and provides substantial improvement in MALDI performance \[[@B3]\].

MALDI matrices are generally small organic compounds and act as energy mediators, effectively transferring the laser energy from a source to the surrounding sample molecules, resulting in minimum fragmentation. The method involves both laser ablation and ionization of the matrix/analyte mixture after electronic excitation of the matrix \[[@B4]\]. It is generally observed that effective LDI matrices have an aromatic conjugated system in their structures which enhance the energy absorbing capacity from UV laser. This phenomenon is still relatively unclear therefore certain molecule can act as matrices and others not \[[@B5]\]. Moreover, routinely used commercially available matrices such as HCCA (α-cyano-4-hydroxycinnamic acid), DHB (2,5-dihydroxybenzoic acid) and SA (sinapinic acid) also get ionized, producing large number of background signals in the low-mass region which restricted the use of MALDI for the determination of low molecular weight analyte. In the investigations of low molecular weight compounds, a number of new matrices and many modifications of the MALDI targets have been accomplished \[[@B6]-[@B25]\].

In an attempt to correlate the performance of a matrix in a MALDI experiment with its chemical structure, we studied thirty one synthetic alternate matrices for their desorption and ionization of intact small peptides. A large number of derivatives of flavones, coumarindione (coumarin derivative) and benzimidazol with necessary functionalities have been screened as potential matrices without any tedious chemical modification or applying expensive procedures.

Experimental
============

Chemicals and reagents
----------------------

HPLC grade methanol, trifluoro acetic acid, acetone, and acetonitrile were purchased from Sigma-Aldrich (USA). All standards, (\[Glu^1^\]-fibrinopeptide B human (Glufib, ≥90%), bradykinin (≥97%) and renin substrate tetra-decapeptide (≥97%), were obtained from Sigma-Aldrich (USA). Cholic acid (≥97%) was obtained from Wako (Japan) while bovine serum albumin (BSA)-digest was purchased from Bruker Daltonics (Germany). Deionized water (Milli-Q) was used throughout the study (Millipore, USA). 2-Phenylenediamine, 4-hydroxy coumarin, ethyl benzoyl acetate, phloroglucinol and the other reagents and solvents used in the preparation of matrices were of synthetic grades, obtained from Sigma-Aldrich (USA).

Preparation of matrix materials
-------------------------------

Benzimidazole derivatives were synthesized by reacting together commercially available 2-phenylenediamine and different substituted aromatic aldehydes in *N*,*N*-dimethylformamide (DMF). The mixture was heated to reflux for 2 h; the progress of the reaction was monitored by TLC. After completion of the reaction, the mixture was allowed to cool to room temperature. Addition of water resulted in precipitation of a solid material, after filtration, the solid benzimidazole derivatives were obtained in high yields \[[@B26]\]. Coumarindione (coumarin derivative) were synthesized by taking a mixture of different substituted benzaldehyde and 4-hydroxy coumarin in water. Heating and stirring was continued for 1--2 h at 100°C. The reaction progress was monitored by TLC. On completion, the solid was filtered and washed subsequently with boiling water and hexane. After drying in vacuum, the coumarindione was obtained as a solid product. Flavones were synthesized by mixing different substituted aromatic β-ketoesters and substituted phenols, followed by irradiation with microwaves 300 W at 100°C for 3 min. The crude product was dissolved in 10% aq. NaOH and washed with diethyl ether. The product was precipitated by adding concentrated HCl, which was filtered, washed with water and vacuum-dried to obtain the desired flavones \[[@B27]\].

Preparation of standard solutions
---------------------------------

Peptide standards, bradykinin and renin substrate tetra-decapeptide, were dissolved in 0.1% TFA: ACN (1:1), while cholic acid was dissolved in methanol (1 mg/mL). The stock solution of peptide standards was prepared in a 1 mM concentration, and working standard solutions of 25 pM were prepared through the dilution of stock solution. BSA-digest was dissolved in 0.1% trifluoroacetic acid (TFA) in a concentration of 4 pM. \[Glu^1^\]-fibrinopeptide B human was used for sensitivity measurements in different concentrations of 1000, 100, 50, 25, 12.5 and 10 pM.

UV--Vis absorption measurements
-------------------------------

Synthesized materials of benzimidazole, flavones and coumarindione derivatives were dissolved in methanol having concentration of 1.0-0.5 mM. The absorption maxima was recorded by UV/Visible scanning in the region of 200--800 nm against the reagent blank on a UV/Visible double beam spectrophotometer (Thermo Scientific Evolution 300, UK), є and Log є were calculated at λ~max~ by Lambert-Beer law.

Instrumentation
---------------

MALDI-MS measurements were carried out on Ultraflex III TOF/TOF (Bruker Daltonics, Bremen, Germany) mass spectrometer, equipped with a smartbeam laser (Nd: YAG, 355 nm, maximum pulse energy of 300 μJ, beam diameter 0.4 mm) and an electrostatic reflector. The focal length of lense is 50 mm. Mass spectra were recorded in reflector mode with the ion source 1 (ISI) set to 25.00 kV, source 2 (ISI) set to 21.50 kV, a lens voltage of 9.51 kV and performed with the laser energies of 55 ± 5%. The validation of data including the baseline subtraction was obtained through Flex analysis. External calibration was carried by using peptide calibration standards (Bruker Daltonics, Bremen,Germany). 0.1% TFA solution was prepared in deionized water and synthetic matrix materials were dissolved in different concentration (1--2 mM) in the solvent system of 0.1% TFA: ACN (1:1). The solution was sonicated for 5 minutes on a sonicator (Ultrasonic LC 38H), followed by centrifugation (Centrifuge 5804R Eppendorf). The supernatant was employed as a matrix. All measurements were made after mixing the matrix solution with analyte at a volume ratio of 1:2, spotted 1.5 μL droplet of mixture on the MALDI target plate (MTP 384, spot diameter 3.5 mm) and allowing the droplet to dry at ambient conditions. The dried droplet preparation method was used for the sample preparation. The dried co-crystallized sample was then analyzed by MALDI-MS. To improve the signal-to-noise ratio, spectral data from every 200 laser shots were summed. Then, the results from 3 different locations on a sample spot were summed. Hence, each point in such spectra corresponds to the summation of over 600 shots. The background spectra of matrices was recorded on off mode (provided in the Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1) while with the analyte, the spectra were recorded on deflection mode in order to minimize all background signals generating from matrix.

Recorded BSA digest spectra with various matrices was submitted to the MASCOT search engine (Matrix Science, London, UK), using UniProt/Swiss-Prot (release July 2010, Homo sapiens, 18055 sequences) as the reference database. Mascot search parameters were as follows: enzyme specificity trypsin, fixed modifications cysteine carbamidomethylation, variable modification methionine oxidation. The maximum number of missed cleavages was set to 3 and mass tolerance at (0.1-0.9 Da). Stereomicroscopic image of matrices spots were recorded by using Nikon SMZ 800 (Japan) fitted with (DS-Vi1) camera.

Results and discussion
======================

Synthesized matrix materials of different classes of compounds, including benzimidazole derivatives (class I, fourteen compounds), coumarindiones (class II, twelve coumarin derivatives) and flavones (class III, six compounds) were evaluated as alternate matrices for the detection of low molecular weight peptides (Table [1](#T1){ref-type="table"}). Wavelength maxima (λ~max~) of synthetic matrix materials were measured to verify their ability to absorb the laser energy at proper λ~max~ employed in ultraviolet-Matrix-assisted laser desorption/ionization mass spectrometry (UV-MALDI-MS). Spectrum quality generally increases with absorption \[[@B28]\], best mass spectrometric performances were observed at wavelengths near absorption maxima of matrices \[[@B4]\]. However, the desorption/ionization process is not solely dependent upon this relationship, as few good working routine matrices have λ~max~ quite far away from N~2~ laser, (377 nm), like nicotinic acid (260 nm), picolinic acid (266 nm), etc. \[[@B29]\]. Therefore, it is often believed that the matrices based desorption/ionization mechanism is still not completely understood. MALDI software generated signal intensities and S/N values (Table [2](#T2){ref-type="table"}) also indicate this anomaly. For instance, compound 3 and 12 having the same λ~max~ i.e. 298 nm, the signal intensity of 12 is one of the highest in both cases of bradykinin and renin substrate tetra-decapeptide, while, intensity levels of compound 3 are among the lowest.

###### 

**The λ**~**max**~**and molar absorptivities of different classes of compounds**

   **S.N**  **Matrix classes**                                                      **Structure**                  **λ**~**max**~**(nm)**   **є**^**a**^   **Logє**
  --------- ----------------------------------------------------------------------- ----------------------------- ------------------------ -------------- ----------
            **Class** (**I**) **Benzimidazole derivatives**                         ![](1752-153X-7-77-i1.gif)                                                 
   **1.**   4-(1*H*-Benzimidazol-2-yl)phenol                                        ![](1752-153X-7-77-i2.gif)              299                19041         4.3
   **2.**   5-(1*H*-Benzimidazol-2-yl)-2-ethoxyphenol hydrate                       ![](1752-153X-7-77-i3.gif)              229                16437         4.2
   **3.**   2-(3-Chlorophenyl)-1*H*-benzimidazole                                   ![](1752-153X-7-77-i4.gif)              298                10987         4.0
   **4.**   2-(1-Naphthyl)-1*H*-benzimidazole                                       ![](1752-153X-7-77-i5.gif)              230                13705         4.1
   **5.**   2-(3,4-Dimethoxyphenyl)-1-phenyl-1*H*- benzimidazole                    ![](1752-153X-7-77-i6.gif)              223                24942         4.4
   **6.**   2-(1*H*-Benzimidazol-2-yl)-5-hydroperoxyphenol                          ![](1752-153X-7-77-i7.gif)              315                20238         4.3
   **7.**   2-(4-Isopropylphenyl)-1*H*-benzimidazole                                ![](1752-153X-7-77-i8.gif)              298                19812         4.3
   **8.**   3-(1*H*-Benzimidazol-2-yl) phenol                                       ![](1752-153X-7-77-i9.gif)              213                 7143         3.8
   **9.**   2-(1*H*-Benzimidazol-2-yl)-4-chlorophenol                               ![](1752-153X-7-77-i10.gif)             214                 9313         4.0
   **10.**  2-(4-Ethoxyphenyl)-1*H*-benzimidazole                                   ![](1752-153X-7-77-i11.gif)             298                14002         4.1
   **11.**  *N*, *N*-Dimethyl-4-(1-phenyl-1*H*-benzimidazol-2-yl) aniline           ![](1752-153X-7-77-i12.gif)             325                28295         4.4
   **12.**  2-(3,4-Dimethoxyphenyl)-1*H*-benzimidazole                              ![](1752-153X-7-77-i13.gif)             298                15107         4.2
   **13.**  2-(3,4-Dichlorophenyl)-1*H*-benzimidazole                               ![](1752-153X-7-77-i14.gif)             309                17452         4.2
   **14.**  2-(1*H*-Benzimidazol-2-yl)-1,4-benzenediol                              ![](1752-153X-7-77-i15.gif)             213                13545         4.1
            **Class**-**11** (**Coumarin derivative**)                              ![](1752-153X-7-77-i16.gif)                                                
   **15.**  3-\[(5-Methyl-2-furyl)methylidene\]-2*H*-chromene-2,4-dione             ![](1752-153X-7-77-i17.gif)             213                16009         4.2
   **16.**  3-\[(2-Bromophenyl)methyl idene\]-2*H*-chromene-2,4-dione               ![](1752-153X-7-77-i18.gif)             213                10209         4.0
   **17.**  3-\[(2-Nitrophenyl)methyl idene\]-2*H*-chromene-2,4-dione               ![](1752-153X-7-77-i19.gif)             214                16985         4.2
   **18.**  3-\[(2,4-Dihydroxy phenyl)methylidene\]-2*H*-chromene-2,4-dione         ![](1752-153X-7-77-i20.gif)             212                15120         4.2
   **19.**  3-\[2-Furylmethylidene\]-2*H*-chromene-2,4-dione                        ![](1752-153X-7-77-i21.gif)             214                16067         4.2
   **20.**  3-\[(2,3,4-Trihydroxyphenyl) methyl idene\]-2*H*-chromene-2,4-dione     ![](1752-153X-7-77-i22.gif)             213                16720         4.2
   **21.**  3-\[(2-Ethoxyphenyl)methyl idene\]-2*H*-chromene-2,4-dione              ![](1752-153X-7-77-i23.gif)             213                23618         4.4
   **22.**  3-\[(2-Hydroxy-3-methoxy phenyl)methylidene\]-2*H*-chromene-2,4-dione   ![](1752-153X-7-77-i24.gif)             214                11682         4.1
   **23.**  3-\[(2-Fluorophenyl) methylidene\]-2*H*-chromene-2,4-dione              ![](1752-153X-7-77-i25.gif)             213                13596         4.1
   **24.**  3-\[(3-Fluorophenyl) methylidene\]-2*H*-chromene-2,4-dione              ![](1752-153X-7-77-i26.gif)             279                21981         4.3
   **25.**  3-\[(4-Hydroxyphenyl)methyl idene\]-2*H*-chromene-2,4-dione             ![](1752-153X-7-77-i27.gif)             298                16720         4.2
   **26.**  4-Methyl-2*H*-chromen-2-one                                             ![](1752-153X-7-77-i28.gif)             324                 5779         3.8
            **Class**-**III** (**Flavones**)                                        ![](1752-153X-7-77-i29.gif)                                                
   **27.**  7-Hydroxy-2-phenyl-4*H*-chromen-4-one                                   ![](1752-153X-7-77-i30.gif)             306                17642         4.2
   **28.**  5-Methyl-2-phenyl-4*H*-chromen-4-one                                    ![](1752-153X-7-77-i31.gif)             261                15211         4.2
   **29.**  5,7-Dihydroxy-2-phenyl-4*H*-chromen-4-one                               ![](1752-153X-7-77-i32.gif)             268                22629         4.4
   **30.**  2-(3,4-Dimethoxyphenyl)-4*H*-chromen-4-one                              ![](1752-153X-7-77-i33.gif)             334                17175         4.2
   **31.**  2-(3,4-Dimethoxyphenyl)-7-methyl-4*H*-chromen-4-one                     ![](1752-153X-7-77-i34.gif)             334                14432         4.1

###### 

**Signal intensity and S**/**N ratio of synthetic matrix material with low molecular weight analytes**

  **Compounds**    **Bradykinin**^**a**^   **Renin substrate tetra-decapeptide**^**a**^        
  --------------- ----------------------- ---------------------------------------------- ----- --------
  **1**                     711                               56530                       551   47162
  **2**                     540                               23276                       423   23276
  **3**                     547                               61687                       228   23778
  **4**                     447                               64184                       205   50958
  **5**                     965                               179163                      579   39417
  **6**                     612                               73058                       450   40258
  **7**                     403                               98986                       586   132521
  **8**                     710                               105850                      689   68272
  **9**                     148                               254785                      435   32688
  **10**                    250                               38696                       411   59285
  **11**                    568                               129858                      361   80878
  **12**                    524                               157277                      360   144048
  **13**                    548                               58187                       620   105141
  **14**                    520                               131703                      668   127967
  **15**                    612                               17858                       402   55811
  **16**                    369                               24724                       463   65700
  **17**                    250                               57522                       432   81912
  **18**                    332                               101983                      299   61957
  **19**                    294                               55402                       200   13615
  **20**                    286                               13022                       514   14110
  **21**                    244                               53297                       446   36294
  **22**                    427                               88683                       642   101135
  **23**                    455                               85541                       650   53205
  **24**                    328                               11451                       519   81163
  **25**                    850                               16992                       574   85517
  **26**                    402                               14593                       436   79334
  **27**                    370                               26798                       444   66542
  **28**                    202                               10398                       221   13736
  **29**                    727                               115238                      309   124664
  **30**                    708                               10452                       125   16030
  **31**                    806                               89386                       66    18759
  **HCCA**                  832                               86824                       792   147702

^a^ 25pM.

Method optimization
-------------------

Two important parameters, including are sample preparation method and solvent selection, which played an important role in getting a better signal to noise ratio (S/N) \[[@B30],[@B31]\]. One member of each class was used for optimization of the method before screening all the synthetic compounds. Sample preparation is one of the most important factors in MALDI-MS analysis. Three different commonly used sample preparation methods for laser desorption/ionization (LDI) were tried and compared by using different synthetic matrices, while 0.1% TFA: ACN was used as the suspending solvent. According to method A, the sample was mixed with synthetic matrix solution in a ratio of 1:2 and placed on a target plate. In method B, a thin layer of 1 μL of synthetic matrix material solution was made on a target plate and then 0.5 μL of analyte was added to it. Method C involves a similar strategy as that of method B, except that the synthetic matrix solution was placed on top of the sample matrix layer (sandwich method). Analysis of bradykinin as an analyte under three different conditions showed that method A was the best sample spotting method and it was therefore selected for the study (Figure [1](#F1){ref-type="fig"}). The preference of method A was based on the high signal intensity and better S/N ratio. Similarly, the solvent used for the solution/suspension of newly evolved matrix materials is another important factor in sample preparation. Different solvent systems, such as acetone, methanol, acetonitrile, (1:1) water/methanol, (1:1) water/acetonitrile, and 0.1% TFA: ACN were used. 0.1% TFA: ACN was selected due to the better results of the above-mentioned mass spectral parameters (Figure [1](#F1){ref-type="fig"}).

![Solvent and method optimization of various matrices with bradykinin.](1752-153X-7-77-1){#F1}

Screening of compounds
----------------------

All synthetic compounds were prepared for screening in 0.1% TFA: ACN with matrix to analyte volume ratio of 1:2 for the detection of low molecular weight peptides, bradykinin and renin substrate tetra-decapeptide (\<2000 Da).

Fourteen compounds of class I (benzimidazole derivatives) possessing λ~max~ around 213--325 nm, were screened. All these new synthetic matrices of class I was comparable to existing MALDI matrix, HCCA in terms of intensity for the detection of peptides. However, the new matrices showed almost no background signals in the low mass range and hence were found to be suitable for the analysis of small peptides. Compounds 5, 8, 9, 11, 12 and 14 showed very high intensity (\>1× 10^5^) for peptides (Table [2](#T2){ref-type="table"}).

Twelve compounds of class II (coumarindione) were also screened as LDI matrix. All of them showed high intensity (\>1× 10^4^) for low molecular weight peptides. Moreover, coumarin derivatives possess λ~max~ between 212--324 nm, most of the compounds showed best results. However, coumarin dyes \[[@B32]\] and 3-hydroxycoumarin \[[@B33]\] have been reported as a MALDI matrix for the analysis of proteins and oligodeoxynucleotides, respectively. Five compounds of class III (flavones), possessing λ~max~ between 261--334 nm, were also tested as LDI matrices. Both peptides showed good signal intensity (\>1× 10^4^) as presented in Table [2](#T2){ref-type="table"}.

Benzimidazole derivatives (1--14) posses different aromatic substitution at C-2. Aromatic ring substituted with electron withdrawing (halogen) and electron donating (−OH, -NR, -OR, R) groups at various positions. Compounds 6 and 14 which possess the same groups but at different orientations on phenyl ring i.e. *meta* and *para*, respectively, and it was found that *para* oriented OH groups exhibited better results. Moreover, in compound 12, when hydrogen at N-1 was substituted with phenyl ring as in compounds 5 then a decline in peptide signals were observed. In case of coumarins, compounds possessing furan ring (15 and 19) showed weak signals, whereas in dimethoxy substituted coumarin analogue (18) showed an enhanced signal in all coumarin derivatives. In flavone derivatives, dihydroxy containing flavone (29) showed high signal intensity as compare to compound 28 which lacks hydroxyl residues. Overall, signal intensities of analytes analyzed by newly developed matrices were promising. In all classes, different substituents were attached which to act as an auxochrome through electron lone pair on hetro atom and conjugated double bond system. Both n-π\* and π-π\* transitions enhanced the hyperchromic effect and lead to a bathochromic shift thus resulted an increase in wavelength. This means, less energy is required for the excitation. This factor is directly related to the amount of laser power required to get a good intensity signal from a sweet spot on MALDI target. There were a large number of interfering signals observed in lower mass range with HCCA whereas the spectra recorded with the new matrices were very clean with nominal interfering signals (Figure [2](#F2){ref-type="fig"}). 0.1 mM cholic acid solution was analyzed with three different matrices (compounds 6, 25 and 29) with a standard deviation of only ± 0.033, showing excellent reproducibility among all the matrices. The bradykinin peptide was analyzed with compounds 6, 25 and 29 with a standard deviation of ± 0.088 (Figure [3](#F3){ref-type="fig"}).

![**MALDI mass spectra of cholic acid (M.wt = 408**.**58 Da,0.1 μM),recorded in reflector mode by averaging 600 laser shots with smart beam (355 nm)on MALDI-TOF-MS by applying different compounds as a matrix (A)6 (B)25 (C)29 (D)HCCA.**](1752-153X-7-77-2){#F2}

![**MALDI mass spectra of a peptide bradykinin (25 pM),recorded in reflector mode by averaging 600 laser shots with smart beam (355 nm)on MALDI-TOF-MS by applying different compounds as a matrix (A)6 (B)25 (C)29.**](1752-153X-7-77-3){#F3}

Selected numbers of each class of compounds were subjected to various screening. Sensitivity measurement of \[Glu^1^\]-fibrinopeptide B was carried out by using compound 29 as an LDI matrix (Figure [4](#F4){ref-type="fig"}). Different concentrations of the analyte were screened including 1000, 100, 50, 25, 12.5 and 10 pM which showed intensity of 4 × 10^4^, 2 × 10^4^, 1.7 × 10^4^, 1.0 × 10^4^, 4.0 × 10^3^ and 3.0 × 10^3^, respectively. This unambiguously established the capability of new matrices to detect the less abundant analytes. Moreover, selected compounds from each class, including 6, 25 and 29, were also screened with BSA-digest sample which showed promising signals of peptides in the complex biological samples (Figure [5](#F5){ref-type="fig"}), assignment of significant peaks are mention in the Additional file [1](#S1){ref-type="supplementary-material"}: Table S1. The resulting mass spectrum was subjected to database search against Swiss-Prot, using MASCOT for the identification. The % sequence coverage of BSA using compound 6 was 53 and found to be close with HCCA 61 (Table [3](#T3){ref-type="table"}), proving that the newly synthetic matrices posses ability to analyze peptides in complex biological samples.

![**Sensitivity measurement mass spectra of compound 29 with different concentration of \[Glu1\]-fibrinopeptide B Human recorded in reflector mode by averaging 600 laser shots with smart beam (355 nm)on MALDI-TOF-MS (A)1000 (B)100 (C)50 (D)25 (E)12.5 (F)10 pM.**](1752-153X-7-77-4){#F4}

![**MALDI mass spectra of BSA-digest with compound 6 recorded in reflector mode by averaging 600 laser shots with smart beam (355 nm)on MALDI-TOF-MS.**](1752-153X-7-77-5){#F5}

###### 

**Data**-**base search results of BSA**-**digest**, **analyzed with various matrices**

  **Compounds**    **Average Mascot Score**   **Average number of Peptides**   **% Sequence coverage**
  --------------- -------------------------- -------------------------------- -------------------------
  **6**                       68                            27                           53
  **25**                     101                            17                           28
  **29**                      41                            16                           29
  **HCCA**                    81                            35                           61

The homogeneity of newly synthetic matrices with the analyte solutions was also investigated. The achievement of the best spectral parameters (resolution, intensity and S/N ratio) is attributed to the homogeneous mixing/embedding of analyte molecules into the matrix molecules. This homogeneity makes the finding of sweet spots easier and is particularly useful near the detection limit ranges. Moreover, In MALDI-MS analyses, the matrix should co-crystallize homogeneously with the analyte, and this phenomenon is helpful when recording of MALDI-MS spectra is carried out in an automatic mode. Figure [6](#F6){ref-type="fig"} shows the stereomicroscopic (SM) surface images obtained using different synthetic matrices materials that deposit on the sample target plate. The images showed homogeneous mixing and crystal formation of various matrices with the analyte samples and thus finding of the sweet spot is efficient and offers better reproducibility of results.

![**Microscopic image of cocrystallized analyte of bradykinin with various matrices (A)6 (B)25 (C)29 (D)HCCA.**](1752-153X-7-77-6){#F6}

Conclusion
==========

Thirty one new matrices for laser desorption/ionization mass spectrometry (LDI-MS) have been studied and offered high performance and sensitivity which make them efficient platform for the analysis of small peptides. A number of conjugated aromatic systems in their structures ensure the laser energy transformations to the analytes. Furthermore, screening of a large number of organic compounds with various functionalities will be helpful for the development of structure--property relationship models, which in turn, could lead to a better understanding of the MALDI mechanism and discovery of better matrices in future.
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